KALA लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (29 Jun 2024 @ 01:30):
Our systems believe the stock currently is overvalued by -0.38% compare to its pairs and should correct downwards.

Stats
आज की मात्रा	1.07M
औसत मात्रा	207 193
बाजार मूल्य	19.97M
EPS	$-4.20 ( Q1 \| 2024-05-14 )
अगली कमाई की तारीख	( $-4.41 ) 2024-08-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.490 (Sector) 42.63 (Industry) 0
ATR14	$0.0460 (0.65%)

ACOR -24.02%

ACRX 7.50%

ADMP 0.85%

ADMS 0.00%

AGRX -1.40%

AKAN -3.75%

ALIM 0.54%

AMPH -0.87%

AMYT 0.00%

ANIP 0.94%

AQST 0.39%

ASRT -5.34%

ATNX 0.00%

AVDL -1.75%

AYTU 0.00%

BFRI -2.39%

BGXX -34.22%

CLVR -2.22%

COLL -0.74%

CPIX 0.66%

CRDL 1.00%

CRON -0.43%

CYTH 5.83%

DCPH 0.00%

DERM 9.73%

DRRX -5.49%

DVAX -1.23%

EGRX 11.55%

EMBC 0.32%

EMBCV -9.33%

EOLS -0.73%

ESPR -3.90%

EVOK 5.48%

FLGC 6.71%

FLXN 0.00%

GHSI -0.35%

HCM -1.83%

HROW -0.52%

HUGE -4.71%

IMCC 2.20%

INCR 2.03%

IRWD 5.16%

ITCI -3.51%

IXHL 10.53%

JUPW 11.76%

KALA 9.92%

KIN 0.11%

KMDA -1.78%

LNTH -1.25%

NBIX 2.50%

NEPT 0.00%

NLTX 1.45%

OGI -3.75%

OPTN -3.70%

ORGO 6.06%

PAHC -2.50%

PCRX 2.51%

PETQ -0.45%

PLXP 0.00%

PPD 0.00%

PROC -0.40%

PRPH -2.11%

PTPI 2.69%

RDHL -2.58%

RDUS 4.30%

REPH -0.48%

RGC -5.88%

RMTI 0.00%

SCTL 0.92%

SCYX -1.48%

SIGA 3.13%

SISI -13.33%

SNDL -1.04%

SNOA 1.05%

SSIC 1.03%

SUPN -0.45%

SXTC -2.24%

THTX 0.00%

TKNO -1.44%

TLGT -13.85%

TLRY -4.05%

TXMD -7.47%

TYHT -3.90%

UPC -1.97%

VTRS 1.43%

ZYNE 2.36%

Insider Trading

Date	Person	Action	Amount	type
2024-06-28	Baker Bros. Advisors Lp	Buy	0	Common Stock
2024-06-28	Baker Bros. Advisors Lp	Buy	0	Common Stock
2024-06-28	Baker Bros. Advisors Lp	Buy	263 900	Series F Preferred
2024-06-28	Baker Bros. Advisors Lp	Buy	207 300	Series H Preferred
2024-06-28	Baker Bros. Advisors Lp	Buy	982 600	Series G Preferred

INSIDER POWER
84.03
Last 94 transactions
Buy: 1 241 312 \| Sell: 68 032

सहसंबंध (AI algo v.1.1b): Overvalued: -0.38% $7.13 paired level. (एल्गो वास्तविक समय में सबसे अधिक सहसंबंधित स्टॉक्स के परिवर्तनों का ट्रैक करता है और तत्काल अद्यतन देता है)

मात्रा सहसंबंध

लंबा: 0.36 (neutral)

छोटा: -0.62 (weak negative)

Signal:(44.537) Neutral

Kala Pharmaceuticals Inc सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Kala Pharmaceuticals Inc सहसंबंध - मुद्रा/वस्त्र

0.62
( weak )

0.60
( weak )

0.00
( neutral )

0.65
( weak )

-0.57
( weak negative )

-0.60
( weak negative )

Kala Pharmaceuticals Inc वित्तीय

Annual	2023
राजस्व:	$0
सकल लाभ:	$-303 000 (0.00 %)
EPS:	$-17.35

FY	2023
राजस्व:	$0
सकल लाभ:	$-303 000 (0.00 %)
EPS:	$-17.35

FY	2022
राजस्व:	$3.89M
सकल लाभ:	$1.33M (34.22 %)
EPS:	$-0.150

FY	2021
राजस्व:	$11.24M
सकल लाभ:	$7.14M (63.55 %)
EPS:	$-136.13

Financial Reports:

No articles found.

Kala Pharmaceuticals Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Kala Pharmaceuticals Inc

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.